Skip to main content
. 2020 Nov 27;5(6):e001079. doi: 10.1136/esmoopen-2020-001079

Figure 2.

Figure 2

PFS per IRRC in ITT, I/P-risk and FAV-risk patients. FAV, favourable; I/P, intermediate/poor; IRRC, independent radiology review committee; ITT, intent-to-treat; NIVO+IPI, nivolumab plus ipilimumab; PFS, progression-free survival; SUN, sunitinib.